Methylprednisolone caused an increase in death after head injury

Roberts, I; Yates, D; Sandercock, P
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p5
Academic Journal
The article reports that methylprednisolone caused an increase in death after head injury. A loading dose of methylprednisolone, 2 g over 1 hour in a 100-mL infusion followed by a maintenance infusion of 0.4 g over 48 hours in a 20-mL/h infusion. In patients with head injury, administration of methylprednisolone for 48 hours was associated with an increase in death at 2 weeks.


Related Articles

  • COMMENTARY: Methylprednisolone caused an increase in death after head injury. Qushmaq, Ismael; Cook, Deborah // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p5 

    The article reports that methylprednisolone caused an increase in death after head injury. Corticosteroids are used for patients with traumatic head injury to a variable degree worldwide. A meta-analysis of 13 randomized trials in adults with this condition suggested benefit but did not exclude...

  • Simplifying infusion calculations. Brooks, R.J.; Wilson, A. Murray // British Medical Journal (Clinical Research Edition);1/26/1985, Vol. 290 Issue 6464, p291 

    Examines the methods in simplifying infusion of drugs calculations. Factors contributing to the complexity in the administration of infusion; Relation between drug dosage rate and the volume; Requirements in performing infusion.

  • Assessment of Agents for the Treatment of Head Injury: Problems and Pitfalls in Trial Design. Maas, A.I.R. // CNS Drugs;2000, Vol. 13 Issue 2, p139 

    Over the past decade many neuroprotective agents have been developed with the hope of being able to improve outcome in patients with acute cerebral disorders, such as stroke, head injury and subarachnoid haemorrhage. Unfortunately, in the field of head injury none of the phase III trials...

  • RX For Success. Silberman, Steve // Wired;Sep2009, Vol. 17 Issue 9, p132 

    The article discusses several pills colors that can convince a patient that a placebo is a potent remedy. Yellow pills have been proven to make the most effective anti-depressant while red pills can give a more stimulating kick and green ones can help reduce anxiety. Scientists said that...

  • Effects of Ondansetron on Gastric Tone and Motility Changes Induced by a Prolonged Intraduodenal Infusion of Nutrients. Results of a Placebo-Controlled Study. Maud Brung-Lefebvre; Mickael Bouin; Céline Maillot; Philippe Denis; Philippe Ducrotté // Digestive Diseases & Sciences;Oct2007, Vol. 52 Issue 10, p2676 

    Abstract  Our aim was to study the 5-HT3 antagonist, ondansetron, on gastric motility changes induced by duodenal infusion of nutrients. First, the effects of a 2-hr intraduodenal infusion (IDI) of a caloric diet on antral motility were assessed. Second, a crossed-over...

  • Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Wei Zhao; Lopez, Emmanuel; Biran, Valérie; Durrmeyer, Xavier; Fakhoury, May; Jacqz-Aigrain, Evelyne // Archives of Disease in Childhood;Jun2013, Vol. 98 Issue 6, p449 

    Objective Because pharmacokinetic data are limited, continuous infusions of vancomycin in neonates are administered using different dosing regimens. The aim of this work was to evaluate the results of vancomycin therapeutic drug monitoring (TDM) under three different dosing regimens and to...

  • New drug and dosage form.  // American Journal of Health-System Pharmacy;6/15/2005, Vol. 62 Issue 12, p1238 

    The article presents information about new drugs and dosage form. The lipopeptide is indicated for the treatment of esophageal candidiasis and the prophylaxis of candidal infections in patients who have undergone hematopoietic stem cell transplantation. The recommended dosage for the treatment...

  • RNAi Market Boosted by Price, Ease.  // Drug Discovery & Development;Feb2005, Vol. 8 Issue 2, p15 

    This article reports that within a short span of six years, ribonucleic acid interference (RNAi) technology has been transformed from a molecular novelty lo being identified as a breakthrough technology platform for applications in target validation and therapeutics. Pharmaceutical and...

  • In Silico Drug Discovery: Solving the “Target-rich and Lead-poor” Imbalance Using the Genome-to-drug-lead Paradigm. Pang, Y. P. // Clinical Pharmacology & Therapeutics;Jan2007, Vol. 81 Issue 1, p30 

    Advances in genomics, proteomics, and structural genomics have identified a large number of protein targets. Virtual screening has gained popularity in identifying drug leads by computationally screening large numbers of chemicals against experimentally determined protein targets. In that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics